atherosclerotic cardiovascular disease

Patients who need PCSK9 inhibitors cant get themStudy: PCSK9 inhibitors are being rejected by insurers at very high rates even in high-risk patients like those with familial hypercholesterolemia.
Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.